Payment overview · 2025
General Payments
$620.18
8 reported records · 5 companies
Healthcare provider profile · identity verified
Kenneth D Calhoun, MD
Allopathic & Osteopathic Physicians|Family Medicine · LOUISVILLE, KY · NPI 1225093222
Verified facts
What the public records show
CMS Open Payments records show Kenneth D Calhoun, MD received $620.18 in general payments during 2025 across 8 reported records.
Phathom Pharmaceuticals, Inc. accounted for 39.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $245.13 | 39.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $125.00 | 20.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $110.94 | 17.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $94.50 | 15.2% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $44.61 | 7.2% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $620.18 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $245.13 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $110.94 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $94.50 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $44.61 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $44.61 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 312 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 70 |
| Prednisone | Prednisone | 224 | 161 |
| Metformin Hcl | Metformin Hcl | 216 | 55 |
| Alprazolam | Alprazolam | 186 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 176 | 51 |
| Montelukast Sodium | Montelukast Sodium | 159 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 38 |
| Lisinopril | Lisinopril | 145 | 41 |
| Gabapentin | Gabapentin | 142 | 30 |
| Simvastatin | Simvastatin | 133 | 34 |
| Meloxicam | Meloxicam | 128 | 48 |
| Trazodone Hcl | Trazodone Hcl | 128 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 32 |
| Carvedilol | Carvedilol | 113 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 17 |
| Omeprazole | Omeprazole | 96 | 23 |
| Glimepiride | Glimepiride | 95 | 21 |
| Torsemide | Torsemide | 95 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 73 | 62 |
| Losartan Potassium | Losartan Potassium | 73 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 24 |
| Ozempic | Semaglutide | 68 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 26 |
| Allopurinol | Allopurinol | 63 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 63 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 61 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 15 |
| Clonazepam | Clonazepam | 60 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 14 |
| Azithromycin | Azithromycin | 58 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 14 |
| Celecoxib | Celecoxib | 55 | 21 |
| Eliquis | Apixaban | 55 | 13 |
| Furosemide | Furosemide | 54 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 45 |
| Fenofibrate | Fenofibrate | 53 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 16 |
| Alendronate Sodium | Alendronate Sodium | 51 | 15 |
| Amoxicillin | Amoxicillin | 51 | 38 |
| Potassium Chloride | Potassium Chloride | 51 | 11 |
| Levofloxacin | Levofloxacin | 48 | 47 |
| Meclizine Hcl | Meclizine Hcl | 46 | 16 |
| Mupirocin | Mupirocin | 45 | 29 |
| Tramadol Hcl | Tramadol Hcl | 45 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 12 |
| Ezetimibe | Ezetimibe | 42 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 40 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 11 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 12 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 24 |
| Fluconazole | Fluconazole | 30 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 22 |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 11 |
| Lorazepam | Lorazepam | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Oxazepam | Oxazepam | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | 12 |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Restasis Multidose | Cyclosporine | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Acetic Acid | Acetic Acid | 11 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $620.18 · 8 records | Phathom Pharmaceuticals, Inc. | Auvelity, Kerecis GraftGuide, Kerecis SurgiClose, NURTEC ODT, VOQUEZNA, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error